Updated ESMO Clinical Practice Guideline for esophageal squamous cell carcinoma and insights from 2022 on potential future treatment options
Dr Elizabeth Smyth discusses the updated ESMO Clinical Practice Guideline for the treatment of patients with ESCC and shares her expert insights on potential future treatment options.view bio and disclosures 3/4 Next Chapter
Learning Objectives & Overview
In this activity, Dr Elizabeth Smyth, a consultant in gastrointestinal oncology, shares her expert insight and interpretation of the latest advances in the management of patients with esophageal squamous cell carcinoma (ESCC) using immunotherapy, as well as the potential implications for clinical practice.
After watching this activity, participants should be better able to:
- Describe the efficacy data for emerging treatments, including first- and second-line immunotherapy, for ESCC
- Recall the safety data for emerging treatments for ESCC
- Discuss how the latest data for emerging treatments for ESCC could impact clinical practice
Faculty & Disclosures
Dr Elizabeth Smyth
Addenbrooke’s Hospital, Cambridge, UK
Elizabeth (Lizzy) Smyth is a consultant in gastrointestinal (GI) oncology at Addenbrooke’s Hospital in Cambridge, UK. Dr Smyth commenced her oncology training in Dublin, Ireland. In 2009 she was awarded an Irish Society of Medical Oncology fellowship to train at Memorial Sloan Kettering Cancer Center, New York, NY, USA. Following this, she worked at the Royal Marsden Hospital in London, UK from 2011 to 2018. Her research focus is on clinical trials and translational research in gastroesophageal cancer and she has worked on trial design and management of national and international trials. She is a member of the European Society of Medical Oncology (ESMO) GI Educational Committee and leads the European Organisation for Research and Treatment of Cancer (EORTC) GI Trials Group Gastric Cancer Taskforce. Dr Smyth is committed to furthering national and international collaboration in GI trials research.
Dr Elizabeth Smyth discloses: Consultancy/advisory fees from AMAL Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Merck, Novartis, Pfizer, Roche, Servier and Zymeworks; and Grant/research funding from Bristol Myers Squibb.